Immatics Announces First Quarter 2023 Financial Results and Business Update
16 mai 2023 07h00 HE
|
https://immatics.com/
ACTengine® IMA203 TCR-T monotherapy against PRAME showed 67% confirmed ORR in an interim clinical update on heavily pre-treated 11 patients in Phase 1b dose expansion Cohort A with median duration of...
Immatics veröffentlicht klinisches Daten-Update aus laufender Phase-1b-Zelltherapie-Studie mit ACTengine® IMA203 TCR-T-Monotherapie in Kohorte A gegen die Zielstruktur PRAME
02 mai 2023 07h00 HE
|
Immatics N.V.
Live-Webcast am Dienstag, den 2. Mai, um 14:30 Uhr MESZ Update umfasst Daten von 11 stark vorbehandelten Patienten nach Letztlinientherapie in der Phase-1b-Dosisexpansionskohorte A, die mit der...
Immatics Reports Interim Clinical Data from Ongoing Phase 1b Cohort A Monotherapy with ACTengine® IMA203 TCR-T Targeting PRAME
02 mai 2023 07h00 HE
|
https://immatics.com/
Company to host conference call today, May 2, at 8:30 am EDT / 2:30 pm CEST Update covers data from 11 heavily pre-treated, last-line patients in Phase 1b dose expansion Cohort A treated with IMA203...
Immatics gibt erstes Opt-in von Bristol Myers Squibb für TCR-T-Zelltherapiekandidaten aus aktueller strategischer Multi-Target-Kollaboration bekannt
01 mai 2023 07h00 HE
|
Immatics N.V.
Bristol Myers Squibb hat die erste Option in Anspruch genommen und eine globale Lizenzvereinbarung mit Immatics für den ersten TCR-T-Zelltherapie-Produktkandidaten abgeschlossen; die bestehende...
Immatics Announces First Bristol Myers Squibb Opt-in of TCR-T Candidate from Ongoing Multi-target Strategic Collaboration
01 mai 2023 07h00 HE
|
https://immatics.com/
Bristol Myers Squibb exercised its first option and entered into a global license agreement with Immatics for the most advanced TCR-T product candidate from the companies’ ongoing collaboration to...
EvolveImmune Therapeutics Reports First Results from CRISPR-Cas9 T Cell Exhaustion Screening Platform at American Association for Cancer Research (AACR) Annual Meeting 2023
18 avr. 2023 09h00 HE
|
EvolveImmune
Novel Technology Identified Genes that Promote T Cell Exhaustion, and which are Unique from PD-1/PD-L1 Checkpoint Pathway Engineered CAR-T Cells Lacking Exhaustion-Associated Genes Mediate Improved...
EvolveImmune Therapeutics Presents New Preclinical Data Demonstrating Improved Anti-Tumor Potential of Novel Costimulatory T Cell Engager Platform at Festival of Biologics Immunotherapy World Congress
22 mars 2023 07h00 HE
|
EvolveImmune
Company Unveils EVOLVE-105 Program, A Best-in-Class CD20xCD3 Multispecific Antibody Designed to Concurrently Drive CD2 Costimulation to Improve the Treatment of B cell Malignancies Expanding...
Immatics veröffentlicht Ergebnisse des Geschäftsjahres 2022 sowie ein Update zur Geschäftsentwicklung
21 mars 2023 07h31 HE
|
Immatics N.V.
ACTengine® IMA203 TCR-T-Monotherapie gegen die Zielstruktur PRAME zeigte in einer Zwischenanalyse der klinischen Daten im Oktober 2022 eine bestätigte objektive Ansprechrate (confirmed objective...
Immatics Announces Full Year 2022 Financial Results and Corporate Update
21 mars 2023 07h31 HE
|
https://immatics.com/
ACTengine® IMA203 TCR-T monotherapy against PRAME showed 50% confirmed objective response rate (cORR) at or above target dose in different solid cancers in an interim clinical update in Phase 1a and...
BioNTech to Acquire InstaDeep to Strengthen Pioneering Position in the Field of AI-powered Drug Discovery, Design and Development
10 janv. 2023 07h15 HE
|
BioNTech SE
Acquisition to enable creation of a fully integrated, enterprise-wide capability to discover, design and develop next-generation immunotherapies at scale by leveraging artificial intelligence and...